Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck

This article was originally published in The Pink Sheet Daily

Executive Summary

DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.

You may also be interested in...



AstraZeneca Puts Academics’ Triple Reuptake Inhibitor On Fast Track

Depression drug won’t be just another “me too” compound, says co-inventor at Mayo Clinic.

AstraZeneca Puts Academics’ Triple Reuptake Inhibitor On Fast Track

Depression drug won’t be just another “me too” compound, says co-inventor at Mayo Clinic.

DOV Out-Licenses Pain Candidate Bicifadine To XTL

XTL shifts bicifadine’s development away from “novel indications in acute and chronic pain” to neuropathic pain, firm says.

Related Content

Topics

UsernamePublicRestriction

Register

PS063651

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel